Converge Bio

Company Overview

Snapshot

Founded in May 2024, Converge Bio operates with 11–50 employees and has raised a total of $33M across multiple funding rounds from 4 investors. The company recently secured a grant in June 2026 to expand its AI gene discovery capabilities from pharmaceuticals to climate-resilient crops.

Business overview

Converge Bio is revolutionizing biological R&D through its Generative AI platform, which focuses on DNA, RNA, and protein sequences. The company's core technology aims to accelerate drug discovery and development, serving the biotechnology and pharmaceutical industries within the broader Health Tech & Life Sciences sector.

Strategic signal

In June 2026, Converge Bio secured a $2.5M grant to extend its AI gene discovery capabilities beyond pharmaceuticals to include climate-resilient crops. This expansion signals a strategic diversification of its Generative AI platform, demonstrating its potential applicability across multiple high-impact sectors and opening new market opportunities for investors.

Company Intelligence Q&A

What is Converge Bio's primary focus?

Converge Bio is focused on revolutionizing biological R&D by creating a Generative AI platform for DNA, RNA, and protein sequences, aiming to accelerate drug discovery and development.

When was Converge Bio founded?

Converge Bio was founded in May 2024.

What was a significant recent development for Converge Bio?

In June 2026, Converge Bio secured a $2.5M grant to expand its fast-track AI gene discovery capabilities from pharmaceuticals to growing climate-resilient crops.

Which investors participated in Converge Bio's January 2026 funding round?

In January 2026, Converge Bio received funding from Bessemer Venture Partners and Vintage Investment Partners.

What product did Converge Bio use to improve cancer treatment?

In May 2026, Converge Bio used its ConvergeAB product to improve a popular cancer treatment with a single prompt.